Most people receive one to three Y90 radioembolization sessions, though there is no fixed universal cap. The actual number depends on how your liver responds to each treatment, how much healthy liver tissue remains, and whether the tumor is responding. Some patients are treated in a single session, others undergo sequential treatments targeting different parts of the liver, and a smaller number receive additional rounds if the cancer progresses after an initial response.
Why There’s No Set Maximum
Unlike chemotherapy, which often follows a predetermined number of cycles, Y90 treatment decisions are made one session at a time. Each round delivers targeted radiation directly into the blood vessels feeding a tumor, and the radiation dose accumulates in liver tissue over time. The healthy liver can tolerate significantly more radiation from Y90 microspheres than from traditional external beam radiation. External beam therapy tops out around 30 to 40 Gy before risking liver damage, but Y90 microspheres have been well tolerated at doses up to 80 Gy with no radiation-related liver damage in some studies. That’s because the tiny radioactive beads concentrate their energy in and around the tumor rather than spreading it across the whole organ.
Still, each treatment takes a toll on liver function, and the cumulative effect matters. Your medical team reassesses before every potential session, looking at how your liver is holding up, whether the tumor responded, and whether it’s safe to deliver another dose.
How Retreatment Decisions Are Made
Before approving a repeat Y90 session, your team checks several things. First, they look at how the tumor responded to the previous treatment. If the cancer progressed rapidly within the first six weeks after treatment, that’s generally a sign Y90 isn’t working well enough to justify another round. Patients who showed an initial response but later progressed are better candidates for retreatment.
Your liver function is the other major gatekeeper. Doctors evaluate your bilirubin levels, platelet counts, clotting ability, and overall liver health score (a grading system that ranges from A to C, with C being the most impaired). People with the most advanced liver dysfunction are not offered retreatment because their remaining healthy tissue can’t absorb additional radiation safely.
Your overall physical condition also factors in. You need to be functional enough in daily life to tolerate the procedure and its recovery. If fatigue, weight loss, or other health issues have significantly worsened since the last session, retreatment may be off the table.
The Pre-Treatment Safety Check
Before each Y90 session, including repeats, your team runs a mapping procedure. This involves injecting a tracer into the liver’s blood supply and scanning to see where the particles would land. The goal is to confirm two things: that the microspheres will reach the tumor and that they won’t leak into the lungs or other organs through abnormal blood vessel connections.
If more than 20% of the tracer escapes to the lungs, treatment is typically canceled. Between 10% and 20%, the dose may be reduced. These shunt pathways can change over time, especially after a previous treatment, which is why the mapping scan is repeated before every session, not just the first one. New collateral blood vessels can develop between treatments, creating paths that didn’t exist before.
Sequential vs. Repeat Treatments
It helps to understand the difference between two common scenarios that both involve multiple sessions. In a sequential approach, the liver is treated in stages on purpose. For example, the right lobe might be treated first, followed by the left lobe several weeks later. This is planned from the beginning and counts as a single course of therapy delivered in two parts. Many patients undergo this two-session approach as their standard treatment plan.
A true “repeat” or “retreatment” is different. This happens when cancer returns or progresses after an initial course of Y90, and the team decides another round is warranted. Retreatment targets areas that have already received radiation, which raises the stakes because that tissue has already absorbed a dose. The cumulative radiation load on surrounding healthy liver cells becomes the limiting factor.
Radiation-Induced Liver Injury
The main risk that caps the number of treatments is radiation damage to healthy liver tissue. This condition shows up as a significant spike in liver enzymes (more than five times normal levels) or a noticeable decline in liver function within three months of treatment. The risk climbs with each session and is closely tied to how healthy your liver was going into treatment.
Patients with well-preserved liver function before treatment face a relatively low risk, around 7% in some studies. But for those whose liver is already moderately impaired, the rate jumps to 30 to 50%. This is the core reason why repeat treatments become progressively harder to justify. Each round leaves less functional reserve, and at some point the risk of permanently disabling the liver outweighs the potential benefit of treating the tumor.
What This Means in Practice
For most patients with liver cancer or cancer that has spread to the liver, the realistic range is one to three total treatment sessions. A common pathway looks like this: an initial course (one or two sessions covering different parts of the liver), followed by monitoring with imaging every few months. If the cancer comes back or grows, a second course may be considered if your liver function and overall health still meet the criteria. A third round is less common but not unheard of.
Some patients receive only a single session because the tumor responds well and doesn’t return, or because their liver function declines enough that retreatment isn’t safe. Others may get more than three sessions if their liver tolerates treatment unusually well and the cancer is confined to treatable areas. The 2024 joint practice guidelines from major radiology and nuclear medicine societies don’t specify a hard numerical limit, reinforcing that the decision is individualized.
The key takeaway is that Y90 retreatment is not automatically ruled out after any specific number of sessions. It’s a rolling evaluation: if your liver is functioning well enough, the tumor is in a treatable location, and the mapping scan shows safe particle distribution, another round remains an option.